A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

Trial Details

NCT ID

NCT06994195

Phase

PHASE3

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• BL-B01D1
• Liposomal doxorubicin, Paclitaxel or Topotecan

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Voluntarily sign the informed consent form and comply with the protocol requirements;
• Age: ≥18 years old;
• Expected survival time ≥3 months;
• Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.